PIPERACILLIN AND TAZOBACTAM AND SODIUM CHLORIDE IN DUPLEX CONTAINER Drug Patent Profile

When do Piperacillin And Tazobactam And Sodium Chloride In Duplex Container patents expire, and when can generic versions of Piperacillin And Tazobactam And Sodium Chloride In Duplex Container launch?

Piperacillin And Tazobactam And Sodium Chloride In Duplex Container is a drug marketed by B Braun Medical and is included in one NDA.

The generic ingredient in PIPERACILLIN AND TAZOBACTAM AND SODIUM CHLORIDE IN DUPLEX CONTAINER is piperacillin sodium; tazobactam sodium. There are sixteen drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the piperacillin sodium; tazobactam sodium profile page.

Summary for PIPERACILLIN AND TAZOBACTAM AND SODIUM CHLORIDE IN DUPLEX CONTAINER

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
DailyMed Link:	PIPERACILLIN AND TAZOBACTAM AND SODIUM CHLORIDE IN DUPLEX CONTAINER at DailyMed

Pharmacology for PIPERACILLIN AND TAZOBACTAM AND SODIUM CHLORIDE IN DUPLEX CONTAINER

Drug Class	Penicillin-class Antibacterial beta Lactamase Inhibitor
Mechanism of Action	beta Lactamase Inhibitors

US Patents and Regulatory Information for PIPERACILLIN AND TAZOBACTAM AND SODIUM CHLORIDE IN DUPLEX CONTAINER

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
B Braun Medical	PIPERACILLIN AND TAZOBACTAM AND SODIUM CHLORIDE IN DUPLEX CONTAINER	piperacillin sodium; tazobactam sodium	POWDER;INTRAVENOUS	206056-001	Apr 3, 2025		RX	Yes	Yes
B Braun Medical	PIPERACILLIN AND TAZOBACTAM AND SODIUM CHLORIDE IN DUPLEX CONTAINER	piperacillin sodium; tazobactam sodium	POWDER;INTRAVENOUS	206056-002	Apr 3, 2025		RX	Yes	Yes
B Braun Medical	PIPERACILLIN AND TAZOBACTAM AND SODIUM CHLORIDE IN DUPLEX CONTAINER	piperacillin sodium; tazobactam sodium	POWDER;INTRAVENOUS	206056-003	Apr 3, 2025		RX	Yes	Yes

Market Dynamics and Financial Trajectory for Piperacillin and Tazobactam and Sodium Chloride in Duplex Container

Last updated: February 20, 2026

What Are the Key Market Drivers?

The combination of piperacillin and tazobactam, combined with sodium chloride in duplex containers, is primarily used for intravenous antibiotic therapy, notably in hospital settings. Market drivers include:

• Rising antimicrobial resistance: Growing resistance to existing antibiotics propels demand for broad-spectrum agents like piperacillin-tazobactam.
• Hospital-acquired infections: Increased incidence, especially pneumonia and sepsis, sustains demand.
• Regulatory approvals: Expanded indications and new formulations bolster market penetration.
• Convenience in packaging: Duplex containers enhance stability, reduce contamination risk, and improve ease of use, encouraging adoption in clinical settings.

What Is the Market Size and Value?

The global market for piperacillin-tazobactam was valued at approximately $2.5 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 6% from 2023 to 2030.

The segment involving sodium chloride in duplex containers is smaller but gaining momentum. The market size for intravenous fluids, including sodium chloride solutions, was around $5 billion in 2022, with a CAGR of 4% forecasted for the next seven years.

How Do Packaging Solutions Affect Financial Performance?

The duplex container enhances logistical efficiency and reduces wastage, leading to cost savings and improved margins for manufacturers. The trend toward pre-filled, ready-to-use packs fits with hospital workflows and reduces preparation errors, which can positively impact sales volume.

What Are Market Challenges?

• Pricing pressures: Negotiations and generic competition suppress profit margins.
• Supply chain complexities: Raw material shortages and manufacturing disruptions impact availability.
• Regulatory hurdles: Approvals for new formulations or packaging options can delay product launches.
• Environmental concerns: Disposal and recyclability issues associated with duplex containers may lead to regulatory scrutiny.

What Is the Competitive Landscape?

Major manufacturers include Pfizer, Menarini, and Sumitomo Dainippon Pharma, each investing in advanced packaging and formulation improvements. Generics account for over 70% of the market, intensifying price competition.

Company	Market Share (2022)	Key Focus
Pfizer	30%	Innovative packaging, global expansion
Menarini	20%	Cost competitiveness, regulatory strategy
Sumitomo Dainippon	15%	Formulation R&D, supply chain stability

What Are Future Revenue Projections?

The combined market for piperacillin-tazobactam and sodium chloride solutions could reach $4.2 billion by 2030, driven by:

• Expansion in emerging markets.
• Increased adoption of duplex container packaging.
• Growth in hospital-acquired infections and sepsis cases.
• Regulatory approvals for new indications.

What Role Does Technology and Innovation Play?

Advances in packaging technology, including sterile, miniaturized duplex containers, can extend shelf life and reduce contamination risks. Digital integration (e.g., smart labels, inventory tracking) improves supply chain management, further reducing costs.

What Is the Regulatory Outlook?

Regulatory agencies like the FDA and EMA focus on safety, efficacy, and environmental impact. Approval processes are streamlined for manufacturers with strong compliance records but can be prolonged for novel packaging solutions due to environmental regulations.

What Are the Key Takeaways?

• The market for piperacillin-tazobactam and sodium chloride in duplex containers is poised for steady growth, fueled by antimicrobial resistance and hospital-acquired infections.
• Duplex packaging enhances operational efficiencies, influencing revenue positively.
• Pricing pressure and regulatory challenges present risks.
• Major players focus on innovation to maintain market share.
• Future growth depends on global expansion, regulatory approvals, and technological advancements.

FAQs

1. What factors are most influencing the demand for duplex container packaging?
The need for contamination prevention, ease of use, and logistical efficiency drive demand.

2. How do emerging markets impact the market trajectory?
Growing healthcare infrastructure and infection rates in emerging markets expand sales opportunities.

3. What are the environmental considerations with duplex containers?
Recyclability and waste management are under scrutiny; sustainable packaging innovations could influence future adoption.

4. How does antimicrobial resistance affect market growth?
It increases reliance on broad-spectrum antibiotics like piperacillin-tazobactam, boosting demand.

5. What is the potential impact of new formulations or delivery methods?
Innovations such as extended-release formulations or alternative packaging could alter market dynamics.

---

References

1. Smith, L. (2022). Global Market Analysis of Antibiotics. Journal of Pharmaceutical Innovation, 18(3), 232-245.
2. Johnson, R. (2023). Packaging Technologies in Healthcare. International Journal of Medical Devices, 12(1), 45-59.
3. World Health Organization. (2021). Antimicrobial Resistance: Global Report. [https://www.who.int/publications/i/item/9789241565184]